
MPLT Stock Forecast & Price Target
MPLT Analyst Ratings
Bulls say
MapLight Therapeutics is displaying strong potential in the biopharmaceutical space with their innovative approach to targeting neural circuits for central nervous system disorders. With a proven track record through positive Phase 1 trials and a promising drug candidate with convenient dosing, the company's current value of $2.23B is expected to increase significantly upon successful results in ongoing trials for schizophrenia and Alzheimer's disease psychosis. Along with their other ongoing developments, MapLight Therapeutics has a positive financial outlook, but there is a potential for setbacks or slow market adoption.
Bears say
MapLight Therapeutics is a clinical-stage biopharmaceutical company that has strong financials and a promising lead candidate for central nervous system disorders. However, there is still a long road ahead as they are only in Phase 2 trials for their potential treatments. There is potential for market growth and achievement of exclusivity, but competition and potential side effects may hinder success.
This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares